Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.

Nicholas Batt Beverly Rodrigues Stephen BloomR SawhneyElena S George Alexander HodgeN VootukuruC McCraeSurbhi SoodStuart Keith RobertsA DevS BellA ThompsonM C RyanWilliam W KempP J GowSiddharth SoodA J Nicoll

Published in: Journal of gastroenterology and hepatology (2024)

Equal to ALD, MAFLD is now the most common underlying liver disease seen in HCC patients in Australia. Future HCC prevention screening and treatment strategies need to take this important group of patients into consideration.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
mesenchymal stem cells
bone marrow
patient reported outcomes